摘要
目的：探讨培美曲塞二钠联合铂类方案二线治疗晚期非小细胞肺癌（NSCLC）的疗效和不良反应.方法：16例既往化疗失败的晚期NSCLC患者接受培美曲塞二钠联合铂类方案化疗,其中培美曲塞二钠500 mg/m^2加入0.9%氯化钠注射液100 ml静脉滴注超过10 min，第1天；顺铂75 mg/m^2或卡铂剂量AUC=5第2天，静脉滴注.每21 d重复,2周期评价疗效.结果：16例患者中,无CR病例，PR 2例,SD 8例,PD 6例,RR12.6%,DCR为62.5%.主要的不良反应是骨髓抑制、消化道反应和口腔粘膜炎，多为I-Ⅱ度，经对症治疗后可以缓解，不影响继续用药.结论：培美曲塞二钠联合铂类方案二线治疗晚期NSCLC安全有效，耐受性好.
Objective：To investigate the efficacy and adverse reactions of pemetrexed disodium combined with plati-num second-line in the treatment of advanced non-small-cell lung cancer （NSCLC）. Methods：16 cases of advanced NSCLC patients whose past chemotherapy were failure, received pemetrexed disodium combined with platinum-based chemotherapy. On the first day, the pemetrexed disodium 500 mg/m^2 was added into 100 ml 0.9%sodium chloride in-jection and intravenously infused over 10 min;on the second day, the cisplatin 75 mg/m^2 or carboplatin dosage AUC=5 intravenously infused. Repeated every 21 days, and the efficacy was evaluated after 2 treatment cycles. Results：In 16 patients, CR 0 case, PR 2 cases, SD 8 cases, PD 6 cases, RR accounted for 12.6%and DCR 62.5%. The main adverse reactions were bone marrow suppression, gastrointestinal reactions and oral mucositis, most of them wereⅠtoⅡdegree, could alleviate after symptomatic treatment, and did not affect the continued medication. Conclusion：Pemetrexed di-sodium combined with platinum second-line is safe and effective to treat advanced NSCLC, and has a good tolerance.
出处
《内蒙古民族大学学报（自然科学版）》
2013年第6期710-711,共2页
Journal of Inner Mongolia Minzu University：Natural Sciences
关键词
培美曲塞二钠
铂类
晚期非小细胞肺癌
Pemetrexed disodium
Platinum-based
Advanced non-small cell lung cancer
